2025
SJR Q1
JCR Q1 · 5,7
OA
13 matched articles
SCIE
Journal detail
Cancer Biology and Therapy
- Publisher
- Taylor and Francis Ltd.
- Country
- United States · Northern America
- Type
- journal
- ISSN
-
1538404715558576
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,407
- Quartile Q1
- H-Index 138
- Cites/doc 5,76
- Docs (3y) 257
- Cites (3y) 1.431
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 5,7
- 5Y JIF 4,5
- JCI 1,18
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Cancer Research Q2
- Molecular Medicine Q1
- Oncology Q1
- Pharmacology Q1
Areas
- Biochemistry, Genetics and Molecular Biology
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS categories
- Oncology
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,407 | 5,7 | 4,5 | 1,18 | Q1 | 138 |
| 2024 | Q1 | Q1 | 1,202 | 4,6 | 4,1 | 1,01 | Q1 | 134 |
| 2023 | Q2 | Q2 | 0,914 | 4,4 | 4,4 | 0,85 | Q2 | 134 |
| 2022 | Q1 | Q2 | 0,996 | 3,6 | 4,2 | 0,78 | Q2 | 134 |
| 2021 | Q2 | Q2 | 0,888 | 4,9 | 4,5 | 0,82 | Q2 | 134 |
| 2020 | Q1 | Q2 | 1,166 | 4,7 | 4,3 | 0,92 | Q2 | 134 |
| 2019 | Q1 | Q2 | 1,116 | 3,7 | 3,7 | 0,85 | Q2 | 134 |
| 2018 | — | Q3 | — | 2,9 | 3,2 | 0,75 | Q2 | — |
| 2017 | Q1 | Q2 | 1,3 | 3,4 | 3,3 | 0,78 | Q2 | 134 |
| 2016 | Q1 | Q2 | 1,181 | 3,3 | 3,4 | — | — | 134 |
| 2015 | Q1 | Q2 | 1,313 | 2,9 | 3,4 | — | — | 134 |
| 2014 | Q1 | Q2 | 1,688 | 3,1 | 3,6 | — | — | 134 |
| 2013 | Q1 | Q2 | 1,631 | 3,6 | 3,6 | — | — | 134 |
| 2012 | Q1 | Q2 | 1,478 | 3,3 | 3,3 | — | — | 134 |
| 2011 | Q1 | Q2 | 1,263 | 2,6 | 2,9 | — | — | 134 |
| 2010 | Q1 | Q2 | 1,31 | 2,9 | 3 | — | — | 134 |
| 2009 | — | Q2 | — | 2,7 | 3 | — | — | — |
| 2008 | — | Q2 | — | 2,8 | 3,1 | — | — | — |
| 2007 | — | Q2 | — | 2,9 | 3 | — | — | — |
| 2006 | — | Q2 | — | 2,8 | — | — | — | — |
| 2005 | — | Q2 | — | 3 | — | — | — | — |
| 2004 | — | Q2 | — | 3,3 | — | — | — | — |
| 2003 | — | Q2 | — | 3 | — | — | — | — |
| 2002 | — | — | — | — | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | ONCOLOGY | SCIE | Q1 | Q1 | 72/333 |
| 2024 | ONCOLOGY | SCIE | Q1 | Q1 | 82/328 |
| 2023 | ONCOLOGY | SCIE | Q2 | Q2 | 87/322 |
| 2022 | ONCOLOGY | SCIE | Q2 | Q2 | 118/241 |
| 2021 | ONCOLOGY | SCIE | Q2 | Q2 | 98/245 |
| 2020 | ONCOLOGY | SCIE | Q2 | Q2 | 99/242 |
| 2019 | ONCOLOGY | SCIE | Q2 | Q2 | 101/244 |
| 2018 | ONCOLOGY | SCIE | Q3 | Q2 | 124/230 |
| 2017 | ONCOLOGY | SCIE | Q2 | Q2 | 101/223 |
| 2016 | ONCOLOGY | SCIE | Q2 | — | 92/217 |
| 2015 | ONCOLOGY | SCIE | Q2 | — | 105/213 |
| 2014 | ONCOLOGY | SCIE | Q2 | — | 91/211 |
| 2013 | ONCOLOGY | SCIE | Q2 | — | 65/203 |
| 2012 | ONCOLOGY | SCIE | Q2 | — | 75/197 |
| 2011 | ONCOLOGY | SCIE | Q2 | — | 91/196 |
| 2010 | ONCOLOGY | SCIE | Q2 | — | 74/185 |
| 2009 | ONCOLOGY | SCIE | Q2 | — | 73/166 |
| 2008 | ONCOLOGY | SCIE | Q2 | — | 68/143 |
| 2007 | ONCOLOGY | SCIE | Q2 | — | 58/132 |
| 2006 | ONCOLOGY | SCIE | Q2 | — | 52/127 |
| 2005 | ONCOLOGY | SCIE | Q2 | — | 52/123 |
| 2004 | ONCOLOGY | SCIE | Q2 | — | 41/123 |
| 2003 | ONCOLOGY | SCIE | Q2 | — | 38/120 |
| 2002 | ONCOLOGY | SCIE | — | — | — |